Targets › P2RY12
28 programs from 23 companies in 37 trials: 21 Phase 4, 9 Phase 3, 6 Phase 2, 1 Phase 1; Cardiovascular, Neurology, Immunology; next expected readout Dec 2026.
Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. (UniProt, Q9H244)
Open in Phaseline: the race on P2RY12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VA Office of Research and Development | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Silent Brain Infarction | Dec 2026 |
| Seoul National University Bundang Hospital | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Type 2 Diabetes; Cardiac Event | Dec 2026 |
| University of Florida | Prasugrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Coronary Artery Disease; Coronary Arterial Disease (CAD) | Dec 2026 |
| University of Florida | Ticagrelor Purinergic receptor P2Y12 negative allosteric modulator | P2RY12 | Phase 4 | Coronary Artery Disease; Intracranial Arteriosclerosis | Dec 2026 |
| University of Florida | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Coronary Artery Disease | Jan 2027 |
| University of Florida | Cangrelor Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor | P2RY12 | Phase 4 | Coronary Arterial Disease (CAD) | Sep 2027 |
| Corewell Health West | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Peripheral Arterial Disease | Oct 2027 |
| Insel Gruppe AG, University Hospital Bern | P2Y12 inhibitor P2Y12 receptor antagonist | P2RY12 | Phase 4 | Percutaneous Coronary Intervention (PCI) | Dec 2027 |
| Zunyi Medical College | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | ACS - Acute Coronary Syndrome | Apr 2028 |
| Yonsei University | Zastaprazan P2Y12 receptor antagonist | P2RY12 | Phase 4 | Chronic Coronary Syndrome | Jul 2028 |
| Rikke Sorensen | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Myocardial Infarction | Dec 2028 |
| Seoul National University Hospital | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Coronary Artery Disease; Antiphospholipid Syndrome | Dec 2028 |
| Yonsei University | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Stroke | Jul 2029 |
| Todd C. Lee MD MPH FIDSA | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 4 | Staphylococcus Aureus Endocarditis | Jan 2030 |
| Federico II University | Cangrelor Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor | P2RY12 | Phase 4 | Coronary Artery Disease | – |
| Jiangsu vcare pharmaceutical technology | Vicagrel P2Y12 receptor antagonist | P2RY12 | Phase 3 | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Dec 2026 |
| iVascular S.L.U. | 1-month DAPT Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo | P2RY12, TBXA2R | Phase 3 | Coronary Artery Disease | Jan 2027 |
| Ottawa Heart Institute Research Corporation | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 3 | Cardiac Allograft Vasculopathy | Mar 2027 |
| Fondation Hôpital Saint-Joseph | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 3 | CLTI Defined as Rutherford Category 4 or 5 | May 2030 |
| Aarhus University Hospital | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 3 | Covert Brain Infarction | Sep 2031 |
| Kafrelsheikh University | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 3 | Ischemic Stroke | – |
| Kafrelsheikh University | Ticagrelor Purinergic receptor P2Y12 negative allosteric modulator | P2RY12 | Phase 3 | Ischemic Stroke | – |
| St. Antonius Hospital | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 2 | Acute Coronary Syndrome | Jan 2027 |
| University of Sao Paulo | Clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 2 | Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma | Oct 2027 |
| University Hospital, Bordeaux | clopidogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 2 | Scleroderma | Jun 2032 |
| IRCCS San Raffaele | Cangrelor Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor | P2RY12 | Phase 2 | Cardiogenic Shock | – |
| Mazandaran University of Medical Sciences | Ticagrelor Purinergic receptor P2Y12 negative allosteric modulator | P2RY12 | Phase 2 | Ischemic Stroke | – |
| Viatris Innovation | Selatogrel Purinergic receptor P2Y12 antagonist | P2RY12 | Phase 1 | Chronic Coronary Syndrome | – |
Coronary Artery Disease (8) Ischemic Stroke (5) Coronary Arterial Disease (CAD) (3) Chronic Coronary Syndrome (2) Peripheral Arterial Disease (1) Scleroderma (1) Silent Brain Infarction (1) Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) (1) Covert Brain Infarction (1) Intracranial Arteriosclerosis (1) Acute Coronary Syndrome (1) Percutaneous Coronary Intervention (PCI) (1)
small molecule (26), other (1)
University of Florida (4) Kafrelsheikh University (2) Yonsei University (2) iVascular S.L.U. (1) Corewell Health West (1) University Hospital, Bordeaux (1) VA Office of Research and Development (1) Jiangsu vcare pharmaceutical technology (1) Mazandaran University of Medical Sciences (1) Aarhus University Hospital (1) St. Antonius Hospital (1) Insel Gruppe AG, University Hospital Bern (1) Zunyi Medical College (1) Ottawa Heart Institute Research Corporation (1) Seoul National University Bundang Hospital (1) IRCCS San Raffaele (1) Seoul National University Hospital (1) Rikke Sorensen (1) Todd C. Lee MD MPH FIDSA (1) Federico II University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.